Imatinib Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0053 
Minor change in labelling or package leaflet not 
26/09/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0052 
B.III.1.a.2 - Submission of a new/updated or 
19/07/2023 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
from an already approved manufacturer 
IB/0051/G 
This was an application for a group of variations. 
09/06/2022 
21/11/2022 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IG/1508 
A.5.b - Administrative change - Change in the name 
23/05/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0049 
B.II.f.1.d - Stability of FP - Change in storage 
16/11/2021 
21/11/2022 
SmPC, 
To update the storage conditions for Imatinib Teva 100 mg 
conditions of the finished product or the 
diluted/reconstituted product 
Labelling and 
and 400 mg, Capsule, hard. 
PL 
IB/0047/G 
This was an application for a group of variations. 
15/04/2021 
10/05/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Page 2/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0048 
B.III.2.b - Change to comply with Ph. Eur. or with a 
01/04/2021 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IA/0046 
A.7 - Administrative change - Deletion of 
07/01/2021 
10/05/2021 
Annex II and 
manufacturing sites 
PL 
IA/0045/G 
This was an application for a group of variations. 
30/11/2020 
n/a 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Updated certificate from an already approved 
manufacturer 
IB/0044 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/08/2020 
10/05/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
WS/1801 
This was an application for a variation following a 
28/05/2020 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0042 
B.III.1.a.2 - Submission of a new/updated or 
10/01/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0041 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
11/07/2019 
03/07/2020 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IB/0040 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/11/2018 
28/03/2019 
SmPC, 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0039 
B.II.a.3.b.1 - Changes in the composition 
03/08/2018 
n/a 
(excipients) of the finished product - Other excipients 
- Any minor adjustment of the quantitative 
composition of the finished product with respect to 
excipients 
IB/0036 
B.II.b.3.z - Change in the manufacturing process of 
02/08/2018 
n/a 
the finished or intermediate product - Other variation 
IA/0038/G 
This was an application for a group of variations. 
01/08/2018 
n/a 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
N/0037 
Minor change in labelling or package leaflet not 
25/07/2018 
28/03/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0033 
B.II.b.3.e - Change in the manufacturing process of 
05/07/2018 
n/a 
the finished or intermediate product - Introduction or 
increase in the overage that is used for the AS 
Page 5/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0034 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/04/2018 
28/03/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0032 
B.II.e.1.b.1 - Change in immediate packaging of the 
22/11/2017 
n/a 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
R/0028 
Renewal of the marketing authorisation. 
20/07/2017 
18/09/2017 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Imatinib Teva in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IAIN/0031 
B.III.1.a.1 - Submission of a new/updated or 
18/08/2017 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IA/0030 
B.II.d.2.a - Change in test procedure for the finished 
12/06/2017 
n/a 
product - Minor changes to an approved test 
procedure 
II/0026 
B.I.z - Quality change - Active substance - Other 
09/06/2017 
n/a 
variation 
IA/0029 
B.II.d.2.a - Change in test procedure for the finished 
10/05/2017 
n/a 
product - Minor changes to an approved test 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
procedure 
IA/0027/G 
This was an application for a group of variations. 
07/03/2017 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0024/G 
This was an application for a group of variations. 
22/12/2016 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IA/0025 
B.III.1.b.3 - Submission of a new/updated or 
12/12/2016 
n/a 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IB/0023/G 
This was an application for a group of variations. 
09/12/2016 
18/09/2017 
SmPC 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0020 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
10/11/2016 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IAIN/0021 
B.III.1.a.3 - Submission of a new/updated or 
28/10/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IAIN/0019 
B.III.1.a.1 - Submission of a new/updated or 
28/10/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/09/2016 
06/10/2016 
SmPC, 
The marketing authorisation was extended to the 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
indications of “adult patients with newly diagnosed 
PL 
Philadelphia chromosome (bcr-abl) positive (Ph+) chronic 
leukaemia (CML) for whom bone marrow transplantation is 
not considered first line treatment” and “adult patients with 
Ph+ CML in chronic phase after failure of interferon-alpha 
therapy, or in accelerated phase” following an assessment 
of similarity to the currently authorised orphan medicinal 
products for these indications and the documentation in 
support of a request for derogation as laid down in Article 
8.3, paragraph (a) of Regulation (EC) No 141/2000. 
IB/0017 
B.II.b.3.a - Change in the manufacturing process of 
11/07/2016 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IAIN/0016 
C.I.z - Changes (Safety/Efficacy) of Human and 
30/05/2016 
06/10/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0015 
A.7 - Administrative change - Deletion of 
19/04/2016 
17/05/2016 
Annex II and 
manufacturing sites 
PL 
IB/0014 
C.I.z - Changes (Safety/Efficacy) of Human and 
31/03/2016 
17/05/2016 
SmPC 
Veterinary Medicinal Products - Other variation 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0013/G 
This was an application for a group of variations. 
21/12/2015 
n/a 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IA/0011/G 
This was an application for a group of variations. 
09/06/2015 
n/a 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
IB/0010/G 
This was an application for a group of variations. 
20/05/2015 
17/05/2016 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0009/G 
This was an application for a group of variations. 
05/03/2015 
06/05/2015 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
II, Labelling 
and PL 
Page 11/14 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0008 
B.II.b.4.a - Change in the batch size (including batch 
19/01/2015 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
T/0007 
Transfer of Marketing Authorisation from Teva 
06/10/2014 
11/11/2014 
SmPC, 
Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). 
Transfer of Marketing Authorisation 
Labelling and 
PL 
IA/0006/G 
This was an application for a group of variations. 
13/08/2014 
n/a 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IAIN/0005 
B.II.b.2.c.1 - Change to importer, batch release 
06/06/2014 
11/11/2014 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0004/G 
This was an application for a group of variations. 
05/05/2014 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IAIN/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
24/05/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/03/2013 
31/05/2013 
SmPC and PL 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IAIN/0002 
B.II.b.2.b.1 - Change to batch release arrangements 
07/02/2013 
31/05/2013 
Annex II and 
and quality control testing of the FP - Not including 
PL 
batch control/testing 
Page 14/14 
 
 
 
 
 
 
 
 
 
